Webcast Goldman Sachs Global HC Conference, June 12 2019, 11:20 a.m. PT, Palos Verder

2019

argenx to Present at Upcoming Investor Conferences

May 30, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that management will present at two upcoming investor conferences in June:

argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology

May 28, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the publication in Neurology of the results from the completed Phase 2 clinical trial of FcRn-antagonist efgartigimod (ARGX-113) in patients with generalized myasthenia gravis (gMG). The Neurology publication can be accessed here.  

argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

May 22, 2019

  • Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets

  • Highlights formation of two global therapeutic franchises in neuromuscular and hematology with targeted first commercial launch in 2021

  • Appoints Wim Parys, M.D. as Chief Medical Officer, formerly of Janssen

 

May 22, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, will be hosting its second R&D Day today, Wednesday, May 22, 2019, in New York starting at 8:30am ET. During the event, argenx will present data on two new pipeline candidates that emerged from its Innovative Access Program (IAP) and will provide updates on the development plan of cusatuzumab (ARGX-110) in collaboration with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. Today, argenx will also bring forward its “argenx 2021” vision, providing clarity on its strategy to become a fully integrated immunology company.

argenx to Host R&D Day on May 22, 2019

May 15, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host an R&D Day for analysts and investors on May 22, 2019 at 8 a.m. ET in New York City.

argenx reports first quarter 2019 financial results and provides business update

May 09, 2019

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financial results and provided a business update for the first quarter ended March 31, 2019.

argenx to Present at Bank of America Merrill Lynch 2019 Health Care Conference

May 08, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 at 9:20 a.m. PT in Las Vegas, NV.

argenx announces results of Annual General Meeting of Shareholders

May 07, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the proposed resolutions presented at our Annual General Meeting of Shareholders were duly passed at the meeting, which was held today at 10:00 a.m. CET.

argenx announces Annual General Meeting of Shareholders on May 7, 2019

March 26, 2019

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that an annual general meeting of shareholders will be held at 10:00 a.m. CET on Tuesday May 7, 2019 at the at Sheraton Amsterdam Airport, Schiphol Boulevard 101, Schiphol, (municipality of Haarlemmermeer), the Netherlands.

argenx to receive first clinical milestone payment for product candidate developed

March 14, 2019

  • Initiation of first-in-human clinical trial with antibody product candidate ABBV-151 (ARGX-115)

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that ABBV-151, an antibody product candidate formerly named ARGX-115 and exclusively licensed to AbbVie, has now commenced clinical development with the initiation of a first-in-human clinical trial. The attainment of this development milestone triggers a $30 million payment by AbbVie.

argenx to Present at Cowen and Company 39th Annual Health Care Conference

March 04, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 12:00 p.m. ET in Boston.

argenx reports fourth quarter business update and full year 2018 financial results

February 28, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its fourth quarter business update and full year results for 2018.

argenx to host conference call & webcast to report fourth quarter business update and full year 2018 financial results on February 28, 2019

February 21, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, February 28, 2019 at 3:00 pm CET (9:00 am ET) to discuss its 2018 financial results and provide a fourth quarter business update.  

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

February 04, 2019

  • argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn

Breda, the Netherlands / Ghent, Belgium & San Diego – argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx’s lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients.

argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen

January 18, 2019

  • $200 million equity investment made by Johnson & Johnson Innovation – JJDC, Inc.

Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the closing of the exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110), a highly differentiated anti-CD70 SIMPLE Antibody™, with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration agreement became effective following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and the closing of the private placement described below.

argenx to Present at 37th Annual J.P. Morgan Healthcare Conference

January 03, 2019

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10th, 2019 at 10:00 a.m. PT in San Francisco.